JLL Capital Markets announced today that it has closed the acquisition of 9501 Lakeside, a future 76,000-square-foot, cell therapy manufacturing facility located in The Woodlands within Houston, Texas.

JLL represented the tenant, Cellipont Bioservices, and procured the buyer, Vitrian, a fully integrated biomanufacturing and cGMP real estate company.

9501 Lakeside will feature state-of-the-art manufacturing, process development, assay development and testing capabilities and is scheduled to open within the first half of 2023. The opening of this site will expand upon Cellipont’s existing location in San Diego.

The property sits in Research Forest Lakeside (RFL) in The Woodlands, Texas. RFL is a planned development uniquely located on 77-wooded acres overlooking Lake Woodlands that features six office and four retail buildings, with future development of up to three additional class A office buildings totaling 760,000 square feet. The mixed-use site is home to a diverse line up of tenants including chemical, financial services, logistics, oil and gas exploration, LNG shipping and integrated energy companies. RFL’s location provides easy access to all of The Woodlands’ amenities, such as Market Street, The Woodlands Mall and The Woodlands Waterway Marriott Hotel and Convention Center. Additionally, I-45 is less than a five-minute drive away.

The JLL Capital Markets Investment Advisory team representing the tenant was led by Directors Dave Baker and Brian Buglione and Managing Director Kevin McConn.

“JLL is honored to have represented Cellipont, a best-in-class cell therapy CDMO, in achieving this critical milestone in their growth trajectory,” said Baker. “Strong investor interest in this opportunity reflected the strength of Cellipont as a tenant, as well as projected growth in the cell therapy manufacturing space, and investors’ positive reception of the growing Houston life science market. We are excited to watch the future successes of Cellipont and Vitrian together.”